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1. Introduction
The traditional paradigm for autoimmunity dates back over a century to the German bacteri‐
ologist, and early pioneer of immunology, Paul Ehrlich, who postulated that if the immune
system encounters an autoantigen, damaging outcomes ensue. He described the autoimmune
phenomenon as “horror autotoxicus” or the horror of self-toxicity. Today, this basic idea
persists even in the ‘modern era’ utilizing biochemical and molecular-based approaches to
immunology. We are taught that recognition of self as foreign by the adaptive immune system
is the basis for autoimmunity. Thus, the identity of the autoantigen(s) responsible for these
illnesses remains the Holy Grail for scientists committed to uncovering the origins of these
diseases.
While many are focused on the identity of this antigen, we have opted for a slightly different
approach to this centuries-old problem. We would argue that the identity of the autoantigen
is not as important as the cell that sees this antigen. Our approach suggests a failure of the
responding immune cell, particularly the T helper cell. In fact, recognition of self is essential
for T cell survival and immune homeostasis. The immune system must recognize ‘self’ in order
to protect the host.[1, 2] In lieu of traditional approaches that may involve animal models, our
work has focused on the patients and their immune cells to investigate the molecular under‐
pinnings of disease. We have also observed that common therapies to treat autoimmune
disease, particularly, rheumatoid arthritis (RA), while efficacious, have ill-defined mecha‐
nisms elucidating their function. Therefore, a large portion of our investigation of rheumatoid
arthritis examines methotrexate (MTX) responses using in vitro models and primary cells from
RA patients receiving MTX therapy. MTX, which remains the ‘gold standard’ for the treatment
of RA, has become a tool for us to better understand this disease. The resulting body of work
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reveals novel mechanisms not only for low-dose MTX action but has permitted us to learn a
great deal about disease pathogenesis. An important consequence of this MTX-centric
approach, has led to us to uncover new understandings for how the human immune system
may function, which we will explore in this chapter. In general, many molecular defects are
seen in T cells from subjects with RA. MTX alters expression/activity of many of these same
targets in vivo and in tissue culture models. Studies in tissue culture models have allowed us
to unravel some of the phenotypic changes that result from MTX treatment. These are
summarized in Table 1.
Gene Target Status in RA MTX Target MTX Function
c-Fos(FOS) UC + Increases apoptosissensitivity
c-Jun (JUN) UC + Increases apoptosissensitivity
CHEK2
DNA-PKcs (PRKDC)
UE
UE
-
+
-
Increases lincRNA-p21
transcripts
JNK2 (MAPK9) UE +
Increases apoptosis
sensitivity and p53 protein
expression
lincRNA-p21
p21 (CDKN1A)
UE
UE
+
+
Reduces NF-κB activity
Activates cell cycle
checkpoints
p53 (TP53) UE +
Activates cell cycle
checkpoints and reduces
NF-κB activity
NF-κB activity
RanGAP1 (RANGAP1)
OE
UE
+
-
Reduces active NF-κB
-
Table 1. Molecular defects in rheumatoid arthritis and methotrexate targets. UC = unchanged, UE = under expressed,
OE = over expressed.
2. Body
2.1. Rheumatoid arthritis
Rheumatoid arthritis is a chronic, inflammatory condition of the small and large joints
characterized by inflammation of the synovium, or lining of the joint.[3] While the precise
etiology of this disease remains unknown, the growing appreciation for the molecular basis of
this disease has provided several clues. Particular emphasis has been placed on the cell types
found in the joint spaces of patients with active disease.[4, 5] Lymphocytes are the most
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common cell infiltrate found in the synovial space. In fact, of these lymphocytes, the majority
are T lymphocytes making up approximately 30-50% of all infiltrating cell types in the
synovium.[6] Of the T lymphocytes found in the RA synovium, it has been reported that the
majority are CD4+CD45RO+ memory cells.[7] B cells constitute about 5% of the sublining
synovial cells.[7] Clonal expansion of the B cells in the joint spaces of RA subjects suggests a
maturation process driven by an antigen, which still remains unidentified. In normal tissue,
the synovial space is only 1 or 2 cells in depth and is comprised of both Type A (macrophage-
like) and Type B (fibroblast-like) cells.[7] However, in active RA this number increases ten-
fold and is primarily thought to be the consequence of hypercellularlity due to the increase of
both Type A and Type B cells.[7, 8] Many studies have suggested that Type A cells in RA
display an activated phenotype and via circulation are constantly replenished from the bone
marrow. Locally, while in the joint spaces, these Type A, macrophage-like cells produce “pro-
inflammatory cytokines, chemokines, and growth factors” that in turn activate fibroblast-like
synoviocytes and induce these cells to produce additional pro-inflammatory mediators
including “IL-6, prostanoids, and matrix metalloproteinases.” [7, 9, 10] This process can create
both paracrine and autocrine signaling networks that give rise to the chronic synovitis and
recruitment of additional immune cells to the joint, which eventually erodes the extracellular
matrix and destroys the joint space. This phenomenon is referred to as the ‘pannus’, an
expansive synovial tissue.[7] Phenotypically, this pannus closely resembles a tumor. Nuclear
factor κB (NF-κB), a transcription factor that is ubiquitously expressed and functions as a
critical regulator of cell proliferation, differentiation, and inflammation, is also overexpressed
in the RA synovium. Briefly, nuclear factor κB consists of five proteins, c-Rel, RelA (p65), RelB,
p50/p105, and p52/p100 that form either a homodimer or heterodimer.[7, 9] c-Rel, RelA, and
RelB function as the major transactivation subunits. Unless activated, these subunits reside in
the cytoplasm along with their inhibitor, IκB.[7] Phosphorylation of IκB causes IκB to be
degraded by the proteasome, thus releasing NF-κB dimers to migrate to the nucleus where
they localize to promoter regions of target genes.[7] Electromobility shift assays show consti‐
tutively high levels of p50 and p65 proteins in the synovium of rheumatoid arthritis subjects
and induction of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α through IKK
signaling pathways.[9] Depletion of p65 or the IKK family member, IKKβ, in the synovial tissue
with siRNAs or introduction of dominant negative mutants reduces levels of these pro-
inflammatory cytokines.[11]
In addition to increased levels of NF-κB, both synoviocytes and T cells in RA exhibit defects
in expression and function of the guardian protein p53 leading to inability of these cells to
undergo apoptosis and to resulting loss of genomic integrity.[8, 12] p53 is a critical regulator
of cell cycle progression and reduced p53 levels or inactivating p53 mutations have also been
found in a number of cancers including leukemia. Linking the contribution of these observa‐
tions to the pervasive, non-resolving inflammation found in RA is a common goal in the
management of the disease. Without this understanding, most therapeutics lack the specificity
to precisely target the underlying defects contributing to disease progression. As such, most
newly developed biologic agents attempt to disrupt the downstream, NF-κB activation-pro-
inflammatory cytokine loop, by using drugs like etanercept, which selectively blocks the
inflammatory cytokine, TNF-α.[13] These newer biologic therapies have added to the ability
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of physicians to improve outcomes and decrease disability. However, despite these advances
excess mortality observed in patients with RA continues and recent data suggest that the
mortality gap between RA patients and the rest of the population continues to widen.[14, 15]
How, then, can we design therapies to target these observed defects? In the mid-twentieth
century, we witnessed the birth of molecular medicine and the era of intelligent drug design.
While most of the drugs developed during this period sought to treat cancer, very few of these
early medications remain first in class therapies today and have since been replaced by more
targeted therapies. Yet, one drug, MTX, first developed more than a half century ago, remains
the standard of care for the treatment of RA.
2.2. Overview and history of MTX
Folates are critical components of cellular division, and DNA and RNA synthesis. The synthetic
form of folate, folic acid, was first isolated in the early 1940s and was found to exacerbate acute
forms of leukemia when added to a patient’s diet.[16-18] Conversely, additional studies found
that decreasing dietary amounts of folic acid decreased the leukemia cell counts in patients.
From these early observations, work began to design analogues of folic acid, which could be
used to treat cancer, particularly leukemia. Aminopterin was designed to reduce proliferation
of cancerous cells via the inhibition of folate. Seminal work by Sidney Farber, a pathologist at
Harvard Medical School and Boston Children’s hospital, demonstrated that aminopterin
produced remission in children diagnosed with acute lymphoblastic leukemia (ALL).[18-20]
Even though this only produced brief remissions, it was proof of concept that folate antago‐
nism could suppress the proliferation of malignant cells. Thus, the clinical efficacy of amino‐
pterin in the treatment of ALL cemented aminopterin as one of the world’s first
chemotherapeutics.[18]
Work that followed nearly a decade later by Sidney Futterman, Michael Osborn, and Frank
Heunnekens identified dihydrofolate reductase (DHFR) from chicken liver as the enzyme
responsible for the reduction of folic acid to metabolically active forms.[18, 21] Thus, blockade
of DHFR was implicated as a therapeutic target of chemotherapeutic doses of aminopterin.
Isolation of this enzyme allowed for the creation of more potent inhibitors of DHFR. Specifi‐
cally, another folate analog, MTX, was identified in a study of leukemia-bearing mice and when
compared to aminopterin increased survival in these mice.[18] From these initial data in mice,
two reports found that MTX at very high doses cured women diagnosed with choriocarcinoma,
a malignant trophoblastic cancer of the placenta.[19] This was the first solid tumor to be cured
by a drug in humans and stimulated interest in investigating the effects of MTX in additional
forms of cancer.[18, 22] Of particular interest was the reduced side effect profile observed in
the MTX-treated cohort. Compared to radiation or alkylating agents that can lead to infertility
or additional malignancies, MTX monotherapy did not produce these deleterious effects.[18]
Today, MTX is currently used in the treatment of large cell or high grade lymphomas, head
and neck cancer, breast cancer, bladder cancer, and osteogenic sarcoma.[18] It is often used in
combination with other therapies including 6-mercaptopurine (6MP). Studies have shown that
the combination of MTX, 6MP, vincristine, and prednisone improve patient outcomes in the
treatment of ALL.[18] In particular, a treatment regiment first prescribing MTX and following
with 6MP in sequence improves cure rates.[18]
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Given the immunosuppressive potential of aminopterin and MTX in the treatment of malig‐
nancy, Gubner et al reported in 1951 that proliferative responses of formalin injection in rat
paws was abrogated with aminopterin treatment.[18, 23] Further, in a small population of
patients with active rheumatoid arthritis, Gubner and colleagues showed that the overwhelm‐
ing majority of patients treated with aminopterin developed reduced indices of disease
activity. When the therapy was stopped, the patients experienced relapse. The toxicities
reported included nausea and diarrhea, even at low doses (1-2 mg/day).[18] Due to these
discomforts, MTX, which closely resembles aminopterin, was substituted.[18] Patients were
able to tolerate MTX reasonably well at low doses. The role of aminopterin, and later MTX,
was also investigated in other non-neoplastic diseases including psoriasis, a chronic skin
condition producing thick patches of irritated skin that manifest as red or white scales and
similar therapeutic benefits were observed.[18] It is interesting to note that this early report
describing the therapeutic potential of MTX or other folate analogs was largely ignored for a
quarter century. It would not be until the late 1980s that MTX is approved for the treatment of
rheumatoid arthritis.[24]
Given the therapeutic potential for MTX in the treatment of these forms of cancer and even
autoimmune disease, significant resources have been expended to investigate its mechanism
of action. Bertino et al provided significant insight demonstrating that MTX is actively
transported into cells through reduced folate transporter 1 (RFT-1).[25] MTX, like naturally
occurring folates, is polyglutamated once taken up by the cell. Folates exist in cells as poly‐
glutamates through the addition of 6 glutamyl groups in a gamma peptide linkage to the folate
substrate using the enzyme folylpolyglutamate synthase (FPGS).[26] These long-lived MTX
polyglutamates remain in the liver of patients for a long period as well as in the bone marrow
myeloid precursors.[26] Polyglutamation of MTX occurs within 12-24 hours after treatment
and polyglutamates constitute the active form of the drug.[26, 27] Thus, MTX is commonly
referred to as a pro-drug, a compound that undergoes a biochemical modification to become
its active form. Inhibition of DHFR, at pharmacologically relevant doses of MTX required for
the treatment of malignancy, inhibits purine, pyrimidine, and thymidylate biosynthesis
through reduced levels of tetrahydrofolate (FH4) in the cell. Blockade of these enzymes, which
are critical for nucleotide generation, halts rapid division of tumor cells through induction of
apoptosis. Thus, one goal of MTX therapy is to increase the cellular cytotoxicity profile.
Alterations to this pathway in the form of mutated RFT-1 or DHFR can lead to MTX resistance
in cancer patients.[19, 26] Interestingly, cancer subjects resistant to MTX often exhibit increased
levels of DHFR protein. It is hypothesized that gene amplification events may take place that
are long-lived in tumor cells or that amplification occurs through extrachromosomal elements,
called amplisomes, that contain DHFR genes.[26] This is currently an area of active exploration
and future studies are required to determine the exact mechanisms.
While MTX is still used in the modern treatment of cancer, it is in the treatment of rheumatoid
arthritis that physicians have observed MTX’s greatest, long-term effectiveness. Often
heralded as the drug that revolutionized the field of rheumatology, low-dose, once-weekly
MTX differs by approximately three orders of magnitude (milligrams versus grams) compared
to dosing schemes required for the treatment of malignancies. When the FDA first approved
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MTX in 1988 for the treatment of rheumatoid arthritis, it was assumed that the mechanism of
action by which MTX exerts its anti-inflammatory effects in rheumatoid arthritis would closely
resemble the mechanism of action found in the treatment of cancer. However, despite
considerable experience with MTX in the treatment of RA, we are still uncovering clues as to
the exact mechanism or mechanisms MTX employs to produce its anti-inflammatory effects.
2.3. MTX and adenosine
Given the pro-inflammatory, anti-apoptotic phenotype exhibited by both synoviocytes and T
cells in RA, and the ability of MTX to mitigate indices of inflammation it is logical to question
if MTX may exert its anti-inflammatory properties through modulation of these pathways. For
the past 30 years, the precise mechanisms employed by MTX to exert its anti-inflammatory
effects in RA have been the focus of thorough investigation.[18, 25, 28-41] In the treatment of
cancer, MTX induces apoptosis by blocking the folate-dependent processes involved with
DNA and RNA synthesis ultimately leading to cell death. Curiously, however, folic or folinic
acid supplementation in RA patients receiving MTX does not reverse its anti-inflammatory
effects in randomized, blinded trials.[16, 18, 40, 42] Thus, other mechanisms have been
proposed. A prevailing theory is that MTX exerts its mechanism of action through a number
of different mechanisms including release of adenosine that function in parallel to blockade
of nucleotide synthesis.[16] Reduced levels of methyl donors including tetrahydrofolate (FH4)
and methyltetrahydrofolate through inhibition of DHFR blocks generation of lymphotoxic
polyamines through methionine and S-adenosylmethionine (SAM).[17, 27, 36, 40, 42, 43]
Polyamine reduction has been posited as one anti-inflammatory mechanism since polyamines
can be converted to lymphotoxins.[42] However, use of 3-deazaadensoine, a transmethylation
inhibitor, does not demonstrate a significant clinical benefit in RA patients.[42] Yet, low-doses
of MTX also inhibit chemotaxis in monocytes through a process reversed by S-adenosylme‐
thionine supporting the contribution of this pathway in RA.[44] The retention of MTX
polyglutamates in cells exceeds its half-life in plasma, suggesting that the MTX metabolites
persist in tissues. These polyglutamates have also been shown to inhibit aminoimidazolecar‐
boxamidoribonucleotide (AICAR) transformylase resulting in elevated intracellular AICAR
levels. RA subjects exhibit high levels of AICAR in their urine during the course of MTX
therapy.[16, 42] Increased AICAR levels are strong inhibitors of adenosine monophosphate
(AMP) and adenosine deaminases, involved in the consumption of AMP and adenosine to
IMP and inosine. Accumulation of adenosine in tissues has anti-inflammatory effects and
AICARriboside, which also inhibits adenosine deaminase, is increased in RA.[42, 45] MTX has
also been shown to enhance vasodilation leading to increased blood flow through inhibition
of adenosine deamination in whole blood in humans.[46] The direct quantification of MTX-
mediated adenosine release in humans receiving MTX has been unsuccessful largely because
the half life of adenosine in blood and tissue is very brief making these measurements
technically challenging.[42, 47] In animal models, however, the anti-inflammatory effects of
MTX are mediated by adenosine using the carrageenan-induced air pouch model of inflam‐
mation and reversals with A2A adenosine receptor antagonists and supplementation of
adenosine deaminase.[42, 48] Thus, one mechanism by which MTX achieves its anti-inflam‐
matory effects is by stimulating increased synthesis and release of adenosine, which in turn,
activates adenosine receptors to block various pro-inflammatory paths.
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2.4. Novel mechanisms for MTX action
Other studies have also shown that MTX inhibits T cell activation, induces apoptosis, and alters
expression of T cell cytokines and adhesion molecules.[28, 32, 49, 50] Additional work by
Phillips et al posit that the anti-inflammatory properties of MTX are critically dependent upon
the ability to produce reactive oxygen species in both T cells and monocytes, which ultimately
lead to apoptosis.[31] Given the pronounced anti-inflammatory properties of low-dose MTX
therapy in RA, it is unclear how the known biochemical pathways affected by MTX, e.g.
inhibition of DHFR, activation of adenosine synthesis and release, should produce this anti-
inflammatory profile. Our work has sought to explore the question of whether either additional
biochemical pathways are targeted by MTX or additional biochemical consequences of DHFR
inhibition by MTX may produce these anti-inflammatory properties observed in subjects with
RA receiving low-dose MTX as therapy.
While initially developed as a chemotherapeutic, MTX (MTX) has been the mainstay for RA
treatment for nearly four decades. Once-weekly administration of 7.5 to 25 milligrams yields
optimal clinical outcomes, compared to the 5000 mg/week dosage used in the treatment of
malignancy.[16, 18] RA patients treated with MTX experience reduced pain, and improved
joint score and function typically within three months of initiation of treatment. The tight
control and suppression of inflammation in early stages of disease has been advocated as
the basis of documented disease modifying effects. Yet, the mechanisms accounting for the
anti-inflammatory effects of MTX remain incompletely understood. Questions also remain
as to the specific targets necessary to develop new therapeutics beyond MTX for the treatment
of RA.
Our initial studies in RA examined differences in expression patterns of genes in healthy
control subjects and patients diagnosed with autoimmune disease. The goal of these experi‐
ments was to identify a subset of genes that could distinguish between healthy individuals
and patients with autoimmune disease.[51-53] Our expectation was that we would identify
genes that encode proteins typically involved in pro-inflammatory processes. Instead, we
found that patients with RA significantly underexpressed a panel of genes that are typically
considered prototypical ‘cancer genes’ in peripheral blood mononuclear cells that encode
proteins required for cell cycle arrest, maintenance of genomic integrity, and induction of
apoptosis. Many cancers have inactivating mutations in these genes. Specifically, these studies
established that defects in expression of CHEK2, TP53, CDKN1A, and CDKN1B that encode
checkpoint kinase 2, p53, cyclin kinase inhibitor 1A or p21, and cyclin kinase inhibitor 1B or
p27, respectively, conferred an inability for RA lymphocytes to undergo apoptosis in response
to gamma irradiation.[12] The major obstacle moving forward was how to link these obser‐
vations to inflammation and RA disease pathogenesis.
Since mechanisms by which low-dose MTX achieve therapeutic benefit in RA are incompletely
understood and how the above deficiencies in cell cycle regulation and apoptosis may
contribute to RA pathogenesis, we chose to initiate studies to compare RA subjects on MTX to
RA subjects not receiving MTX therapy. Initially, we found that RA subjects receiving MTX
therapy exhibited increased expression of genes encoding Fos and Jun that form the AP-1
transcription factor. In addition, expression of a number of genes induced by the AP-1
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transcription factor is elevated in RA subjects receiving MTX therapy. Further, we were also
able to reproduce these findings in tissue culture models via dose-dependent induction of JUN
and FOS expression in T cells treated with sub-micromolar concentrations of MTX.[54]
One signaling pathway that activates the AP-1 transcription factor is via activation of Jun-N-
terminal kinase (JNK), a MAP kinase, which phosphorylates Jun resulting in increased
transcriptional activity of AP-1. MTX also activates JNK in our tissue culture models and MTX-
dependent activation of JNK is responsible for the observed increases in JUN and FOS
transcript levels and increased AP-1 activity. Through JNK activation, MTX increases the
sensitivity of T cells to undergo apoptosis by production of reactive oxygen species and
alteration of the transcriptional profile in favor of genes whose protein products promote
apoptosis including Jun mRNA. Thus the resistance to apoptosis in RA T cells we described
previously is reversed by MTX treatment. This process is also mediated by MTX-dependent
inhibition of dihydrofolate reductase (DHFR). Besides reduction of folates, DHFR also
catalyzes the reduction of dihydrobiopterin (BH2) to tetrahydrobiopterin (BH4) and BH4 is a
necessary cofactor of all nitric oxide synthases. MTX also blocks the DHFR catalyzed reduction
of BH2 to BH4. Loss of BH4 causes a process called nitric oxide synthase ‘uncoupling’ that results
in production of reactive oxygen species such as hydrogen peroxide by nitric oxide synthases
rather than production of nitric oxide. It is this nitric oxide synthase ‘uncoupling’ that leads to
JNK activation and altered sensitivity to apoptosis.
Since our in vivo studies of RA patients on low-dose MTX therapy revealed elevated levels of
the prototypical JNK-target gene, JUN, in response to MTX, our data support the notion that
the JNK pathway is also activated by MTX, in vivo, and may contribute to the efficacy of MTX
in inflammatory disease. Specifically, we now hypothesize that the therapeutic efficacy of MTX
may arise at least in part from its ability to deplete BH4. BH4 depletion is known to cause a shift
in cytokine profiles from a pro-inflammatory profile to an anti-inflammatory profile and our
work shows that BH4 depletion also increases sensitivity of lymphocytes to apoptosis, a process
that may improve clearance of self-reactive inflammatory lymphocytes by apoptosis.
We further probed the mechanism by which MTX increases sensitivity of cells to apoptosis by
asking if MTX restores the cell cycle checkpoint deficiencies we described previously. Since
MTX increases activity of JNK in our tissue culture models, we asked if levels of JNK are
decreased in subjects with RA not receiving MTX. We found highly significant deficiencies of
MAPK9 (JNK2) expression in rheumatoid arthritis.[55] This represents the major JNK protein
expressed by lymphocytes. Analysis of other MAPK family members including most known
ERK and p38 isoforms did not reveal any significant differences in healthy controls versus RA
cohorts receiving or not receiving MTX. Following our gene expression studies, we analyzed
protein expression in RA lymphocytes and found that these subjects exhibit reduced JNK
protein expression. Analysis of additional autoimmune diseases also indicated that this
MAPK9 deficiency observed in RA was not unique to RA, but also extends to multiple sclerosis
(MS). It is interesting to note that both RA and MS exhibit similar molecular defects in PBMC
specifically through reduced checkpoint kinase 2 (CHEK2), p53 and ataxia telangiectasia (AT)
mutated (ATM) expression.[56] The contributions of JNK to these defects remains to be
explored. We found that MTX increased levels of both p53 and the downstream target p21 in
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MTX-treated cells via JNK, which was further confirmed in vivo by analyzing transcript levels
of TP53 and CDKN1A in subjects receiving and not receiving MTX therapy. These MTX-
mediated effects are critically dependent upon MTX depletion of BH4, generation of ROS, and
activation of JNK. Through loss of ATM, RA T cells accumulate a significant amount of DNA
damage.[57] One hypothesis is that DNA damage repair deficiencies coupled with depressed
levels of p53 and JNK blunt the central pathways of apoptosis resulting in cell survival but
loss of genomic integrity. Cell survival comes at a cost and the cost is persistent DNA damage,
which may activate NF-κB or alternative pro-inflammatory, pro-survival pathways leading to
the ‘sterile inflammation’ observed in RA pathogenesis.
2.5. The cell cycle checkpoint deficiency-NF-κB activation connection in RA
Our studies outlined above clearly establish that MTX is a strong transcriptional activator, both
in tissue culture models as well as in RA patients as part of their therapy. This is achieved in
large part via activation of JNK. One of the best-studied proteins induced by MTX is p53, which
itself is a strong transcriptional activator and the gene expression program induced by p53
allows p53 to carry out many of its cellular functions such as cell cycle arrest and induction of
apoptosis. Further, transcript levels of genes encoding p53 and its transcriptional targets are
largely depressed in RA patients. However, whether losses of these gene transcripts and
corresponding proteins can contribute to the pro-inflammatory state characteristic of RA or
how they might contribute to this pro-inflammatory state is less clear.
The NF-κB transcription factor is probably one of the best-characterized pro-inflammatory
transcription factors. Many genes that encode pro-inflammatory cytokines, chemokines, and
lymphocyte adhesion molecules possess NF-κB binding sites in their promoters and require
activation of NF-κB for their increased expression in response to extracellular inflammatory
stimuli. For these reasons, our next series of experiments analyzed the influence of MTX upon
transcriptional activity of NF-κB, a central regulator of the inflammatory response, in two cells
types: T cells and primary fibroblast-like synoviocytes (FLS) from RA subjects. We also
examined NF-κB activity in the PBMC of RA patients receiving and not receiving MTX. In T
lymphocytes, we found that MTX is a strong inhibitor of activation of NF-κB in response to
various extracellular stimuli. In T cell tissue culture models, MTX inhibits activation of NF-κB
via BH4 depletion and JNK activation. Further, the inhibition of NF-κB activity in T cells by
MTX is dependent upon MTX-mediated induction of p53. In patients with RA, NF-κB activity
is chronically elevated in T helper cells and this elevation is reversed by MTX therapy. Taken
together, we believe these studies provide a direct link between elevated activity of the pro-
inflammatory, pro-cell survival transcription factor, NF-κB in RA and depressed levels of the
pro-apoptotic, pro-cell cycle control transcription factor, p53, and show how induction of p53
by MTX results in subsequent loss of NF-κB activity in RA T helper cells.
Synovial fibroblast-like cells also activate NF-κB in response to extracellular stimuli and
elevated levels of NF-κB activity have been demonstrated in RA synovial tissues. Therefore,
we asked if MTX also inhibits activation of NF-κB in response to extracellular stimuli and if
this inhibition is achieved via BH4 depletion and JNK activation. Low concentrations of MTX
effectively inhibit NF-κB activation in synovial fibroblasts in tissue culture. However, MTX
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does not act by depleting BH4 and activating JNK as it does in T cells. In fact, genes character‐
istically induced by MTX in T cells, e.g. TP53, CDKN1A, JUN, are not induced by MTX in
synovial fibroblasts. This appears to be because nitric oxide synthase enzymes are expressed
at much lower levels in synovial fibroblasts than in T cells and thus generation of reactive
oxygen species via nitric oxide synthase ‘uncoupling’ is inefficient. Rather, inhibition of NF-
κB activation in synoviocytes appears to be mediated by adenosine release and activation of
adenosine receptors.[58] This follows earlier work implicating the potential role of adenosine
synthesis and activation of adenosine receptors in the anti-inflammatory effects of MTX.[27,
29, 45-47, 59-62] Thus, we conclude that MTX modulates NF-κB through distinct mechanisms
and these effects are specific to different cell types (Figure 1).
    FH2  FH4  ADENOSINE     ADENOSINE RECEPTORS   
      (SYNOVIOCYTE PATHWAY) 
 
METHOTREXATE  DHFR          INHIBITION OF 
            NF-κB 
 
    BH2  BH4  NOS ‘UNCOUPLING’    JNK/p53 activation 
      (T CELL PATHWAY) 
 
Figure 1. Schematic illustrating alternate pathways of MTX-mediated inhibition of NF-κB activity in T cells and syno‐
viocytes.
We have explored the connection between NF-κB and p53 further, as these transcription factors
are two central regulators of the adaptive immune response. NF-κB modulates the response
to exogenous stimuli, whereas p53 modulates intrinsic stress responses through initiation of
“cell cycle arrest, apoptosis, or senescence, eliminating clones of cells with DNA damage and
its resulting mutations”.[63] In general terms, NF-κB and p53 are functionally antagonistic.
NF-κB is considered a pro-survival, pro-inflammatory transcription factor while p53 is an anti-
survival, anti-inflammatory transcription factor. The precise mechanisms explaining the
connection between p53 and NF-κB in the context of immune cells remains largely unexplored
and is likely to be stimulus-, cell-, and/or disease-specific. The basic understanding in a healthy
cell is that DNA damage, hypoxia, or oncogene activation elicit p53 responses that activate cell
cycle arrest, senescence or apoptosis, targeting genes that are pro-apoptotic such as PUMA, or
induce cell cycle arrest proteins such as p21.[63, 64] In the context of DNA damage, ATM is
activated which leads to inhibition of MDM-2, an E3 ubiquitin ligase, and subsequent activa‐
tion of p53.[65-67] While classically thought to be a modulator of cell survival or apoptosis,
activation of p53 also creates metabolic consequences via reduced levels of aerobic glycolysis.
[63, 68] One example of this regulation is p53-dependent activation of TIGAR (TP53-induced
glycolysis and apoptosis regulator) that decreases fructose-2,6-bisphosphate levels leading to
lower rates of cellular glycolysis.[63, 69] Like p53, NF-κB is typically activated via post-
translational modifications via degradation of IκB or MDM-2/MDM-4 in response to exoge‐
nous signals such as infectious agents, viruses, toll-like receptor agonists, antigen receptors or
through inflammatory cytokines, such as TNF-α or interleukin-1β.[63] Thus, NF-κB activation
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leads to transcription of mRNAs that encode inflammatory proteins such as: cytokines, IL-6,
GM-CSF; cheomokines, IL-8, RANTES, MCP-1; enzymes, COX-2, PLA2; and adhesion
molecules VCAM-1 and ICAM-1.(9-11, 70] Interestingly, production of pro-inflammatory
cytokines such as IL-1β and TNF-α creates an amplification loop that can lead to constitutive
activation of the NF-κB signaling pathway. Therefore, strict regulation of this pathway needs
to be employed to avoid persistent NF-κB activity, which could create the basis for chronic
inflammatory disease, autoimmunity, and even certain cancers. Metabolically, activation of
NF-κB enhances glycolysis and increases glucose transporters (GLUT3) leading to higher
amounts of glucose uptake.[63]
Examination of the PBMC and synovium of RA subjects demonstrates that NF-κB is signifi‐
cantly overexpressed. Also present are reduced levels of p53. p53 drives induction of genes
that both prevent DNA damage and repair damaged DNA. Together with NF-κB, these master
regulators of internal and external stimuli must achieve a careful balance. Each transcription
factor responds to a different form of cellular stress, adopting two very different strategies that
have evolved into mutually exclusive processes under normal physiologic conditions.[63] It
has also recently become appreciated that the metabolic fates of RA T cells are reprogrammed.
RA T cells are energy deficient as evidenced by reduced glucose consumption, lactate pro‐
duction, and intracellular stores of ATP.[71, 72] Yang et al identified defects in 6-phospho‐
fructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a critical regulator of glycolysis, as
the mediator of the observed defects as constitutive overexpression of PFKFB3 repaired the
glycolytic insufficiency. Most interestingly, the study also demonstrated that deficiencies of
PFKFB3 reduce ROS levels in cells. Our studies with methotrexate suggest that increased ROS
generation is a therapeutic benefit of MTX therapy as apoptotic death of proliferating T cells
is essential for T cell homeostasis. Thus, the contribution of metabolic ‘rewiring’ and the
therapeutic potential of targeting these biomarkers represent attractive targets for clinical
intervention.
To induce cell cycle arrest or apoptosis, the transcriptional program activated by p53 is
mediated, in part, by induction of the long non-coding RNAs (lncRNAs), lincRNA-p21 and
PANDA.[73, 74] lncRNAs are relatively newly discovered species of RNA. lncRNAs are
transcribed from genes that look like protein-coding genes. Approximately 10,000 lncRNA
genes have been discovered in the human genome so they may be as abundant as protein-
coding genes.[75] These genes contain exons and introns and lncRNAs are spliced to mature
lncRNAs just like mRNAs. The difference between lncRNAs and mRNAs is that lncRNAs are
littered with translational stop codons throughout their sequence and thus cannot be translated
into proteins and therefore exist as RNA species. As a class, lncRNAs have multiple functions.
Major functions are the stimulation or inhibition of transcription of protein-coding genes.
These target protein-coding genes are oftentimes, but not always, located in close proximity
in the genome to the gene encoding the effector lncRNA. These lncRNAs generally act by
recruiting the epigenetic machinery to target gene loci to establish activating or repressive
histone marks. lncRNAs also interfere with translation of proteins. Additional mechanisms of
action of lncRNAs are to regulate function, stability and activity of proteins. Thus, lncRNAs
exhibit a broad spectrum of activities that play key roles in many cellular processes.[76-80]
Will Understanding Methotrexate Modes of Action Teach us About Rheumatoid Arthritis?
http://dx.doi.org/10.5772/59901
185
Further, individual lncRNAs can have multiple modes of action. An example is lincRNA-p21.
One function of lncRNA-p21 is to repress transcription of certain genes in response to p53
activation.[73] A second function is to modulate translation of certain mRNAs.[81] A third
function is to modulate the stability of the transcription factor HIF-1α, thus regulating its
activity.[82] A fourth function is to stimulate transcription of CDKN1A, the gene that encodes
p21 required for cell cycle arrest.[83] Thus, besides being abundant species of RNAs, individual
lncRNAs can possess multiple functions, which increases their cellular phenotypic imprint.
Because both transcript and protein levels of p53 and p21 are depressed in RA and are MTX
target genes, we were interested to learn if the lncRNAs, lincRNA-p21 or PANDA, are
differentially regulated in RA and/or may be MTX target genes. We have found that lincRNA-
p21 transcript levels are depressed in RA T cells and lincRNA-p21 is a MTX target gene in T
cells.[84] However, TP53 and lincRNA-p21 levels do not correlate with each other in T cells
from subjects with RA or healthy controls suggesting that levels of p53 do not determine levels
of lincRNA-p21 in T cells as they do in other cell types. Further, although lincRNA-p21 is
strongly induced by MTX in T cells in our tissue culture models and lincRNA-p21 levels are
restored to normal in RA patients receiving MTX therapy, induction of lincRNA-p21 does not
appear to be dependent upon p53 activation under these conditions in these cell types. In T
cells, induction of lincRNA-p21 by MTX is also not mediated by BH4 depletion, nitric oxide
synthase ‘uncoupling’ and JNK activation or by adenosine release and adenosine receptor
activation.[84]
Increased DNA damage is also observed in RA T cells. The two major sentinels of DNA damage
responses are the enzymes ATM and DNA-PKcs and these enzymes are also deficient in RA
T cells.[57] Thus, these enzyme deficiencies may explain the accumulation of DNA damage
observed in RA T cells. In T cells, stimulation with low concentrations of MTX results in
activation of DNA-PKcs (phosphorylation) but not activation of ATM. Induction of lincRNA-
p21 by MTX requires DNA-PKcs activation. In RA T cells, MTX therapy also restores PRKDC
(the gene that encodes DNA-PKcs) transcript levels to normal. Mechanistically, we do not
understand how MTX activates DNA-PKcs and not ATM in T cells. We also do not understand
how activation of DNA-PKcs leads to induction of lincRNA-p21. One obvious mechanism
would be via induction of p53 but this appears not to be the case. It may be that p21 contributes
to this process but that remains to be investigated. Further studies will be necessary to more
fully understand this mechanism.
We also asked if activation of DNA-PKcs and induction of lincRNA-p21 by MTX contributes
to MTX-dependent activation of NF-κB in response to extracellular stimuli, such as TNF-α.
This is clearly the case. Inhibition of DNA-PKcs, but not ATM, reverses MTX-dependent
inhibition of TNF-α mediated NF-κB activation. Further, use of siRNAs to deplete either p53
mRNA or lincRNA-p21 reverses the ability of MTX to inhibit TNF-α mediated NF-κB activa‐
tion. Thus, we conclude from these studies that multiple pathways are activated in T cells by
methotrexate to achieve its anti-inflammatory effects. A graphic summary of the pathways we
have discovered as a result of these studies is summarized in Figure 2.
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Figure 2. Summary of previously known and new mechanisms of methotrexate action
2.6. Other considerations
It has also been shown that telomeres of CD4+ cells are shortened in subjects with rheumatoid
arthritis. On average, the telomeres of lymphocytes and even progenitor cells, such as CD34+
hematopoietic stem cells, are 1.5kb shorter compared to control resulting in accelerated
immune system aging. [85, 86] Given that the immune system divides on average once a year
and the average telomeric base pair (bp) loss is approximately 50bp, the immune system of
RA subjects is approximately 25-30 years older than that of an unaffected individual. This
phenotype is present in early disease and in untreated patients. So a question to ask is how are
these traits conferred? Genetic studies have informed our knowledge of this disease by
revealing the association of human leukocyte antigen (HLA) serotypes with autoimmune
disease susceptibility. In the case of rheumatoid arthritis, susceptibility is associated with the
HLA-DR4 allele. The relative risk for RA is four times greater in carriers compared to unaf‐
fected individuals with current female to male ratios suggesting an approximate 3:1 distribu‐
tion.[87-89] Specifically, HLA-DRB1*04 remains the most important genetic risk factor for
rheumatoid arthritis. If you examine healthy donors, and track the telomeric length of HLA-
DRB1*04 +/- individuals as they age, donors with a positive HLA-DRB1*04 haplotypes exhibit
premature aging in their CD4+ T cells with average telomeric length approximately 1.0-1.5kb
shorter than HLA-DRB1*04 negative individuals.[64-66] It was further observed that this
phenomenon of early immune aging was also found in the neutrophils of HLA-DRB1*04
positive individuals with concomitant accumulation of pre-senescent CD4+ T cells in healthy
HLA-DRB1*04+ individuals measured by accumulation of CD28 null T cells in the total CD4+
lymphocyte population.[90-92]
In general, telomere loss is a measure of what is termed cellular senescence. Cellular senescence
can arise by a number of mechanisms that include DNA damage, deficiencies of DNA damage
response and repair pathways, as well as elevated NF-κB activity. It has also been argued that
Will Understanding Methotrexate Modes of Action Teach us About Rheumatoid Arthritis?
http://dx.doi.org/10.5772/59901
187
cellular senescence is a pathogenic mechanism in RA. Further, in experimental models, loss of
p21, p27 or p53 can produce cellular senescence as well as pro-inflammatory or autoimmune
phenotypes. Similarly, increased NF-κB activation can produce pro-inflammatory or autoim‐
mune phenotypes. These same defects are seen in RA. Thus, one can imagine a continuous
pathogenic loop of deficiencies in proteins involved in DNA damage responses and cell cycle
control and increased NF-κB activity culminating in RA pathogenesis (Figure 3). MTX-
dependent restoration of these deficiencies in DNA damage response and cell cycle control
proteins that culminate in inhibition of chronic NF-κB activation reinforces this point. What is
unclear is if there are dominant ‘drivers’ in this pathway or will any of the aforementioned
defects that arise produce this pathogenic loop? This model raises the question of whether
these defects arise via genetic or environmental mechanisms and understanding this question
may improve our understandings of the origins of this disease. There may be other methods
to interfere with this pathogenic loop. If developed, these methodologies may aid in the
treatment of RA.
3. Conclusions
One hundred years ago, the only drug in the physician armamentarium to manage RA was
aspirin.[93] Soon after, gold salts were commonly prescribed from approximately 1930-1980.
Penicillamine, anti-malarial drugs, and sulfasalazine were subsequently introduced from in
the 1970s and 1980s.[24] However, despite introduction of these pharmacologics, the disease
course of most RA patients progressed and was not adequately controlled. It wasn’t until the
introduction of disease-modifying anti-rheumatic drugs, such as MTX, that physicians saw
significant improvement in long-term outcomes, especially when MTX was combined with
other therapies. When we initiated our studies to examine the anti-inflammatory properties
of MTX, we thought that there would be a single biomarker we could target to achieve the
same outcome with less toxicity, as subjects taking MTX have reported hair loss, nausea, and
fatigue. However, as we examine the molecular basis for this drug in RA, we find that not only
does it stimulate the adenosine pathway, which results in reduced NF-κB activation in FLS,
but it also activates the BH4 pathway and induces lincRNA-p21 in T cells. Both of these
pathways lower NF-κB transcriptional activity and function in vivo in RA.
Targeted therapies that have been approved over the past decade have resulted in many first-
in-class drugs. However, the majority of these first in class drugs were the result of phenotypic
assay screening, and not through targeted approaches.[94] Interestingly, most targeted
approaches result in follow-on drugs that are prescribed in combination with other ‘anchor’
therapies in human disease. An interesting area of future investigation would be to design
small molecules that selectively target BH2 reduction to BH4 and alternatively induce lincRNA-
p21 expression. Given the diverse effects we see both in vitro and in vivo in RA patients receiving
MTX, it would be difficult to envision a single therapy that could supplant the multi-faceted
pathway MTX employs in the management of RA. While these new therapeutics could be of
utility, an important future direction of this work is setting the stage for a better understanding
the origins of the cellular defects we have observed. We would argue that treatment of the
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most proximal events in disease pathogenesis lead to more effective therapeutic strategies and
improved clinical outcomes. Most newly developed therapies attempt to disrupt the down‐
stream NF-κB activation-pro-inflammatory cytokine loop, such as etanercept through block‐
ade of TNF-α. We argue that interfering with the upstream pathways of deficiency cell cycle
arrest and DNA repair will produce improved therapeutic outcomes for subjects with RA. To
this end, we have considered prevailing theories of immunity and autoimmunity. The general
view is that initiation of adaptive immune responses to pathogens is divided into two parts,
the recognition of ‘danger’ via the innate immune system and the recognition of foreign antigen
by the adaptive immune system.[95, 96] It is widely accepted that a breach in tolerance in the
adaptive immune response leads to recognition of self-antigen contributing to autoimmunity.
In this model, the source of ‘danger’ to initiate the immune response to self has never been
completely identified.[95] We would propose a new model whereby the source of ‘danger’ is
actually internal or intracellular and not external, which we plan to explore.
In our model, DNA damage accumulates every day in individuals as a result of environmental
exposures, UV or ionizing radiation, oxidative stress, chemical exposures, cell replication,
inflammatory stress in response to infection, normal metabolic activities produce oxidants, or
smoking.[97-104] Smoking is well established as a significant environmental risk factor for RA.
Normally, activation of cell cycle checkpoints and the DNA damage response machinery repair
DNA damage. However, in RA, via intrinsic mechanisms regulated by the presence of HLA-
DRB1*04 alleles or other pathways, these repair mechanisms, DNA-PKcs, ATM, and cell cycle
checkpoints, JNK2, p53, p21, p27, CHEK2, RANGAP1 are defective, resulting in failure to
repair DNA and loss of genomic integrity.[53, 105-108] Failure to repair DNA and/or cell cycle
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Figure 3. Hypothetical mechanistic loop that connects known molecular defects in RA to pathogenesis.
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checkpoint defects results in chronic NF-κB activation and induction of pro-inflammatory
cytokines, producing a continuous cycle of events causing chronic inflammation, which
underlies the pathogenesis of RA. Future studies are planned to examine the contribution of
these defects to the pathogenesis of RA.
4. Nomenclature
Gene symbol-Protein names
ATM – Atm, Ataxia Telangiectasia Mutated
Functions: senses DNA damage and initiates DNA repair pathways and pathways to induce
cell cycle arrest or apoptosis, also involved in telomere maintenance
PRKDC – DNA-PKcs, DNA-dependent protein kinase catalytic subunit
Functions: senses DNA damage and initiates similar pathways as Atm, also involved in non-
homologous recombination, necessary for successful formation of T and B cell receptors
CHEK2 – Chek2, Chk2, checkpoint kinase 2
Functions: activated by Atm in response to DNA damage, phosphorylates and activates p53
TP53 – p53, tumor protein p53,
Functions: transcription factor, participates in an array of stress responses inducing cell cycle
arrest, apoptosis, senescence, DNA repair, or changes in metabolism.
CDKN1A – Cdkn1a, p21, cyclin-dependent kinase inhibitor 1a
Functions: Inhibits activity of cyclin-CDK2 or –CDK4 complexes to inhibit cell cycle progres‐
sion at G1, p53 target gene
CDKN1B – Cdkn1b, p27, kip1, cyclin-dependent kinase inhibitor 1b
Functions: Inhibits activity of cyclin E-CDK2 or cyclin D-CDK4 complexes to inhibit cell cycle
progression at G1, p53 target gene
MAPK9 – Mapk9, Jnk2, c-Jun N-terminal kinase
Functions: Phosphorylates a number of transcription factors including c-Jun to activate the
AP-1 transcription factor and regulate stress responses and apoptosis, also pro-inflammatory
as many genes that encode cytokines and chemokines have AP-1 binding sites in their
promoter
JUN – c-Jun, Jun proto-oncogene
Functions: along with Fos, forms the AP-1 transcription factor
FOS – Fos, c-Fos
Functions: along with Jun, forms the AP-1 transcription factor
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RANGAP1 – RanGAP1, Ran GTPase activation protein 1
Functions: GTPase activator for the nuclear Ras-related protein, Ran, and converts it from the
active state to the GDP-bound inactive state
RelA – NF-κB p65 subunit, nuclear factor-kappa B
Functions: transcription factor involved in many cellular processes commonly categorized as
a pro-survival, pro-inflammatory transcription factor
Telomeresregions of repetitive DNA sequences at the ends of each chromosome, telomere ends
shorten after each cell division, cellular senescence occurs when the telomeres become too short
and this inhibits further cell division
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